Please login to the form below

Not currently logged in
Email:
Password:

Nycomed strengthen CEE presence

Swiss company buys 20 branded generics from sanofi-aventis and Zentiva

Nycomed has agreed to buy 20 branded generic products from sanofi-aventis and Zentiva in an attempt to strengthen its market position in Central and Eastern Europe, in particular in the Czech Republic and Slovakia.

Under the terms of the deal, Nycomed will acquire a portfolio of branded generic drugs in the Czech Republic, Slovakia, Romania, Hungary, Estonia and Bulgaria, with an annual turnover of around €17m. In addition, Nycomed will also assume future production.

As part of the deal, Nycomed has purchased Zentiva's well-established hypnotic hypnogen (zolipidem) in the Czech Republic, Slovak Republic and Estonia.

Most of the purchased products are in the Czech Republic and include a strong franchise of beta-blockers (Vasocardin, Betaxa and Tenoloc), which will bolster the company's cardiovascular business around Ebrantil. Other brands include Trental, Flavobion and Ercefuryl.

"These brands will complement our local portfolios very well," said Frank Rotmann, area manager Central and Eastern Europe, Nycomed.

The purchase will be completed as an asset transfer transaction – no further financial details of the deal were available. The European Commission and the Czech Antimonopoly Office have approved the deal, which is expected to close in September 2009. 

3rd August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics